Alzheon
111 Speen Street, Suite 306
Framingham
Massachusetts
01701
United States
Tel: 508-861-7709
Fax: 508-861-1500
Website: http://www.alzheon.com/
Email: info@alzheon.com
About Alzheon
At Alzheon, we apply a precision medicine approach utilizing our scientific knowledge and clinical expertise to make advances in the challenging field of therapeutics for Alzheimer’s and other neurological disorders. Our efforts have resulted in ALZ-801, a novel, investigational medicine with an ideal profile for Alzheimer’s patients: an oral pill with favorable safety and the ability to interfere with the amyloid pathology that leads to Alzheimer’s disease.
106 articles about Alzheon
-
Alzheon to Present Biomarker, Brain Preservation, and Clinical Results from Pivotal Program of Oral ALZ-801/Valiltramiprosate at International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
2/27/2024
Alzheon, Inc. announced its participation in the upcoming International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders in Lisbon, Portugal from March 5–9, 2024.
-
With one disease-modifying therapy already reaching patients and another expected to soon, several biopharma companies anticipate key data for novel assets in the coming 12 months.
-
Alzheon CEO Dr. Martin Tolar to Present ALZ-801/Valiltramiprosate Investigational Oral Alzheimer’s Treatment Program at Nobel Forum at Karolinska Institute in Stockholm, Sweden
1/3/2024
Alzheon, Inc. announced its participation in the Nobel Forum “Challenges for Implementation of New Alzheimer’s Disease Treatments” covering Alzheimer’s therapeutics for the future, at the Karolinska Institute in Stockholm, Sweden from January 18-19.
-
Alzheon CEO Dr. Martin Tolar Awarded Eliška and Zdeněk Strmiska Award from Alzheimer’s Foundation for Significant Contribution Towards Research and Treatment of Alzheimer’s Disease, and Donated Cash Prize to INDRC Institute
1/3/2024
Alzheon, Inc. announced that its Founder, President & CEO Dr. Martin Tolar has been awarded the Eliška and Zdeněk Strmiska Award from the Alzheimer’s Foundation for significant contribution towards the research and treatment of Alzheimer’s disease.
-
Alzheon CEO Dr. Martin Tolar to Discuss Positive Results from Phase 2 Biomarker Study and Upcoming Readout from Pivotal APOLLOE4 Phase 3 Study Evaluating Oral ALZ-801/Valiltramiprosate at Truist Securities BioPharma Symposium
10/31/2023
Alzheon, Inc. announced its participation in the upcoming Truist Securities BioPharma Symposium in New York City, New York on November 8-9, 2023.
-
Alzheon to Present Biomarker, Brain Preservation, and Clinical Results from Pivotal Program of Oral ALZ-801/Valiltramiprosate at 16th Annual Clinical Trials in Alzheimer’s Disease Conference
10/17/2023
Alzheon, Inc. announced its participation in the upcoming Clinical Trials in Alzheimer’s Disease conference in Boston, Massachusetts from October 24-27, 2023.
-
Alzheon To Present Pivotal Program of Oral ALZ-801/Valiltramiprosate at Singularity Conference, Goldman Sachs Alzheimer’s Disease Day, and BIO Investor Forum
9/26/2023
Alzheon, Inc., a clinical-stage biopharmaceutical company developing a portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease and related neurodegenerative disorders, announced that the company will be presenting at upcoming industry and investor conferences.
-
Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Benefits Following 24 Months of Treatment in Phase 2 Trial of Oral ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease
9/13/2023
Alzheon, Inc. announced statistically significant and clinically relevant reduction in plasma biomarkers of neurodegeneration, preservation of brain volume, and positive cognitive effects in Early AD patients who are carriers of apolipoprotein ε4 allele following 24 months of treatment with investigational agent ALZ-801 in the Phase 2 biomarker trial.
-
Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Positive Biomarker/Clinical Correlations from Phase 2 Biomarker Study at AAIC in Amsterdam
7/11/2023
Alzheon, Inc. announced that it will be presenting baseline imaging characteristics from its ongoing APOLLOE4 Phase 3 clinical trial and new correlation analyses from the Phase 2 biomarker study evaluating ALZ-801 oral tablet at the upcoming Alzheimer's Association International Conference, to be held from July 16 – 20, 2023 in Amsterdam, Netherlands.
-
Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Results of Phase 2 Biomarker Study at American Academy of Neurology Conference in Boston
4/18/2023
Alzheon, Inc. announced that it will be presenting baseline imaging characteristics from ongoing APOLLOE4 Phase 3 clinical trial and 12-month results from the Phase 2 biomarker study evaluating ALZ-801 oral tablet at the upcoming American Academy of Neurology Conference to be held from April 22 – April 27, 2023 in Boston, Massachusetts.
-
Alzheon to Present Biomarker, Brain Preservation and Clinical Effects of Oral Tablet ALZ-801 (Valiltramiprosate) at Upcoming AD/PD 2023 Conference in Gothenburg, Sweden
3/22/2023
Alzheon, Inc. announced that it will be presenting interim findings from an ongoing Phase 2 study evaluating ALZ-801 tablet at the upcoming AD/PD 2023 Conference to be held from March 28 – April 1, 2023 in Gothenburg, Sweden.
-
Alzheon Announces Early Completion of Enrollment of APOLLOE4 Phase 3 Clinical Trial Evaluating Oral ALZ-801 (Valiltramiprosate) in APOE4/4 Homozygotes with Early Alzheimer’s Disease
12/6/2022
Pivotal Phase 3 Trial Completed Enrollment Ahead of Schedule Enabling Topline Data Readout and NDA Filing in 2024.
-
Alzheon Inc. unveiled promising data from a Phase II biomarker trial of its investigational drug ALZ-801 to treat early Alzheimer’s disease.
-
Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease
9/20/2022
Alzheon, Inc. reported statistically significant and clinically relevant plasma biomarker reduction, robust preservation of brain volume, and positive memory effects in Alzheimer’s patients following 12 months of treatment with investigational agent ALZ-801 in its Phase 2 biomarker trial.
-
Alzheon Appoints Glenn Pauly as Head of Commercial
9/20/2022
Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease and other neurodegenerative disorders, announced the appointment of Glenn E. Pauly as Head of Commercial.
-
Alzheon to Present Industry-Leading Phase 2 Biomarker and Clinical Data with ALZ-801 (Valiltramiprosate) Oral Tablet at 2022 Alzheimer’s Association International Conference
7/26/2022
Alzheon, Inc. announced that it will be presenting at the 2022 Alzheimer’s Association International Conference to be held on July 31 – August 4, 2022 in San Diego, California, USA. Alzheon Chief Medical Officer, Susan Abushakra, MD, will give a podium presentation at the AAIC conference on Sunday, July 31, 2022, at 8 a.m. PT or 11 a.m. ET.
-
Alzheon to Present ALZ-801 (Valiltramiprosate) Oral Tablet Program Update as Potential Treatment for Alzheimer’s Disease in Adults with Down Syndrome at 4th International Trisomy 21 Research Conference
6/7/2022
Alzheon, Inc. announced that it will be presenting at the 4th International Trisomy 21 Research Society Conference to be held on June 9-12, 2022 in Long Beach, California, USA.
-
The major money winners this week included a DNA editing platform, a machine-learning platform that creates digital patient “twins” and wearable temperature-monitoring patches.
-
Alzheon Appoints Susan Flint as Vice President of Clinical Operations, Patrick Kesslak, PhD, as Vice President of Clinical Development & Medical Affairs, and Erwan de Naurois as Vice President of Finance
4/14/2022
Alzheon, Inc. announced the appointments of Susan Flint as Vice President of Clinical Operations, Patrick Kesslak, PhD, as Vice President of Clinical Development & Medical Affairs, and Erwan de Naurois as Vice President of Finance.
-
Alzheon Announces Closing of Oversubscribed $50 Million Series D Financing Round to Accelerate Completion of APOLLOE4 Phase 3 Trial and Expansion of Product Portfolio
4/14/2022
Alzheon, Inc. announced that it has completed an oversubscribed $50 million Series D round from private and institutional investors.